The link between Onglyza and pancreatic cancer

The link between Onglyza and pancreatic cancer

Many suffering from Diabetes will be acquainted with the drug Onglyza and some will have experienced serious side effects.

In 2013 the medical journal Diabetes published the results of a study that showed signs of pre-cancerous cell growth in people taking DPP-4 inhibitors, the class of drug to which Onglyza belongs. DPP-4 inhibitors increase the production and size of beta cells that produce insulin in the pancreas but according to the research these beta cells are abnormal. Evidence was also found of adenomas which are small tumours that can become malignant.

Pancreatic cancer can be difficult to detect and slow to respond to treatment unless found early. Common symptoms include back/abdomen pain, fatigue, unexplained weight loss and yellowing of the eyes and skin.

If you think you have developed pancreatic cancer as the result of taking Onglyza or have concerns about a late diagnosis of the condition by a health professional, call David Gazzard on 01793 615011.